Ligand Pharmaceuticals LGND Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total revenues and income by Product | |||||
| Captisol | $40.21M+30.2% | $30.88M+8.9% | $28.37M-72.8% | $104.5M-36.4% | |
| Capvaxive | $10.06M— | —— | $0— | —— | |
| Contract revenue | $66.87M— | —— | $17.98M-4.5% | $18.84M— | |
| Filspari | $31.97M+163% | $12.18M+411% | $2.39M— | $0— | |
| Qarziba | $23.74M+113% | $11.12M— | $0— | —— | |
| Vaxneuvance | $7.4M+42.8% | $5.18M+27.6% | $4.06M+275% | $1.08M— | |
| Total revenue and income by Product | |||||
| Evomela | $5.94M-31.5% | $8.68M-15.0% | $10.21M+0.1% | $10.2M+1.2% | |
| Kyprolis | $35.53M-7.4% | $38.38M+7.7% | $35.64M+18.3% | $30.12M+9.6% | |
| Rylaze | $13.35M-2.9% | $13.74M+1.6% | $13.52M+53.7% | $8.8M+263% | |
| Teriparatide injection | $8.15M-0.9% | $8.22M-25.7% | $11.06M-29.9% | $15.79M+200% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ligand Pharmaceuticals break its business down?
- Ligand Pharmaceuticals (LGND) reports total revenues and income by product across 12 parts — Captisol, Capvaxive, Contract revenue, Filspari and Kyprolis. Each is extracted from the segment footnotes and tracked over time.
- Where does Ligand Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ligand Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.